[…] The GSK agreement on corporate integrity has hardly expired and GSK intends to return to these jokes, which are in fact legalized […] Establishment of a salvage provision. The provision of the Executive Financial Recoupment Program provides that GSK implements a program that “presents a risk of loss and reimbursement of up to three years of annual performance compensation – annual bonuses and long-term incentives – for an executive who finds that he has participated in a significant misconduct”. Other pharmaceutical companies that enter into corporate integrity agreements are Abbott Laboratories, Bayer, Cephalon and Eli Lilly. In the future, GSK will be subject to strict requirements as part of its Corporate Integrity Agreement (CIA) with the Department of Health and Human Services (HHS), Office of the Inspector General (OIG). This agreement aims to increase accountability and transparency and to prevent future fraud and abuse. Communications to healthcare providers and paying agencies. As a general rule, pharmaceutical companies that comply with a corporate integrity agreement must inform physicians in writing of the transaction. This agreement goes further by requiring GSK to send letters to the government and other payers with whom the company has discount agreements and inform them of the transaction. Colgan adds that GSK has also “significantly strengthened its compliance program and employee training” in recent years. The company now has eight Compliance Officer Assistant Positions and 79 Integrity Checks. These changes ensure that the company`s programs and activities are well controlled and adapted to the expectations of its stakeholders.

Most importantly, the changes are consistent with the company`s core values and ensure that its operations and relationships are transparent, based on integrity and respect, and focus on the best interests of patients. The company`s U.S. business practices policies now meet or exceed the U.S. PhRMA code that governs interaction with healthcare professionals. Price Report: GSK also resolves allegations that GSK and its predecessors reported fake drug prices between 1994 and 2003, which led to GSK`s under-paid discounts under the medical discount program. By law, GSK was required to declare the lowest or “best” price it charged its customers and to pay quarterly discounts to the states based on those declared prices. If the drugs are sold to buyers in contingency agreements called “Bundles”, the discounts offered for bundled drugs must be redistributed to all products in the Bundle in proportion to the dollar value of the units sold. . .

.